When did Baxter International report Q3 2025 earnings?

Baxter International (BAX) reported Q3 2025 earnings on October 30, 2025 before market open.

What were Baxter International's Q3 2025 revenue and EPS?

Baxter International reported revenue of $2.8B and diluted EPS of $0.69 for Q3 2025.

Did Baxter International beat estimates in Q3 2025?

Revenue beat the consensus estimate of $2.8B by $10.2M. EPS beat the consensus estimate of $0.60 by $0.09.

How did Baxter International's Q3 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 5.0% from $2.7B a year earlier and diluted EPS declined 13.8% from $0.80.

Where can I find Baxter International's Q3 2025 SEC filings?

You can read the 10-Q periodic report (0001628280-25-048897) directly on SEC EDGAR. The filing index links above go to sec.gov.

Baxter International BAX Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$2.8BBeat by $10.2M Diluted EPS$0.69Beat by $0.09

Revenue estimate$2.8B

EPS estimate$0.60

Next report

Jul 30, 2026 (In 5 days)

Revenue estimate$2.8B

EPS estimate$0.36

Financials

Q3 2025

Income statement

See full

Revenue$2.8B+5.0%

Gross profit$950.0M-8.0%

Operating income$172.0M+11.0%

Net income-$46.0M-133%

EPS (diluted)-$0.09-133%

Balance sheet

See full

Cash & equivalents$1.7B+21.5%

Total debt$214.0M-98.4%

Total equity$7.2B-8.0%

Total assets$21.1B-21.0%

Cash flow

See full

Operating cash flow$237.0M-6.3%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Valuation & ratios

Valuation

as of 09/30/25

See full

Market cap$11.7B-39.6%

Enterprise value$10.18B-67.3%

P/S1.1×-0.8×

Profitability

See full

Gross margin34.1%-4.8pp

Net margin-3.1%-4.1pp

FCF margin3.6%-6.2pp

Returns & leverage

See full

Return on equity-4.5%-5.9pp

Debt / equity0×-1.6×

Current ratio1.8×+0.4×

Segments

By product

See full

Infusion Therapies & Technologies$1.0B-4.4%

Care & Connectivity Solutions$473.0M+3.7%

Injectables & Anesthesia$333.0M+3.7%

Advanced Surgery$306.0M+12.5%

Front Line Care$300.0M+1.4%

By segment

See full

Medical Products & Therapies$1.3B-1.0%

Healthcare Systems & Technologies$773.0M+2.8%

Pharmaceuticals$632.0M+7.5%

Versus estimates

Revenue

Q1 2026$2.7BBeat by $85.5M Q4 2025$3.0BBeat by $149.2M

Q3 2025$2.8BBeat by $10.2M

Q2 2025$2.8BMiss by $65.9M Q1 2025$2.6BBeat by $37.5M Q4 2024$10.6BBeat by $8.0B

Diluted EPS

Q1 2026$0.36Beat by $0.05 Q4 2025$0.44Miss by $0.09

Q3 2025$0.69Beat by $0.09

Q2 2025$0.59Miss by $0.01 Q1 2025$0.55Beat by $0.07 Q4 2024$0.58Beat by $0.05

Ask the moment Baxter International reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Baxter International report Q3 2025 earnings?: Baxter International (BAX) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Baxter International's Q3 2025 revenue and EPS?: Baxter International reported revenue of $2.8B and diluted EPS of $0.69 for Q3 2025.
Did Baxter International beat estimates in Q3 2025?: Revenue beat the consensus estimate of $2.8B by $10.2M. EPS beat the consensus estimate of $0.60 by $0.09.
How did Baxter International's Q3 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 5.0% from $2.7B a year earlier and diluted EPS declined 13.8% from $0.80.
Where can I find Baxter International's Q3 2025 SEC filings?: You can read the 10-Q periodic report (0001628280-25-048897) directly on SEC EDGAR. The filing index links above go to sec.gov.